Olawade, David B., Clement David-Olawade, Aanuoluwapo ORCID: https://orcid.org/0000-0002-7052-6425, Adereni, Temitope ORCID: https://orcid.org/0009-0002-3153-0859, Egbon, Eghosasere, Teke, Jennifer and Boussios, Stergios ORCID: https://orcid.org/0000-0002-2512-6131 (2025) Integrating AI into Cancer Immunotherapy—A Narrative Review of Current Applications and Future Directions. Diseases, 13 (1). p. 24.

Preview

Text diseases-13-00024.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Background: Cancer remains a leading cause of morbidity and mortality worldwide. Traditional treatments like chemotherapy and radiation often result in significant side effects and varied patient outcomes. Immunotherapy has emerged as a promising alternative, harnessing the immune system to target cancer cells. However, the complexity of immune responses and tumor heterogeneity challenges its effectiveness. Objective: This mini-narrative review explores the role of artificial intelligence [AI] in enhancing the efficacy of cancer immunotherapy, predicting patient responses, and discovering novel therapeutic targets. Methods: A comprehensive review of the literature was conducted, focusing on studies published between 2010 and 2024 that examined the application of AI in cancer immunotherapy. Databases such as PubMed, Google Scholar, and Web of Science were utilized, and articles were selected based on relevance to the topic. Results: AI has significantly contributed to identifying biomarkers that predict immunotherapy efficacy by analyzing genomic, transcriptomic, and proteomic data. It also optimizes combination therapies by predicting the most effective treatment protocols. AI-driven predictive models help assess patient response to immunotherapy, guiding clinical decision-making and minimizing side effects. Additionally, AI facilitates the discovery of novel therapeutic targets, such as neoantigens, enabling the development of personalized immunotherapies. Conclusions: AI holds immense potential in transforming cancer immunotherapy. However, challenges related to data privacy, algorithm transparency, and clinical integration must be addressed. Overcoming these hurdles will likely make AI a central component of future cancer immunotherapy, offering more personalized and effective treatments.

Item Type:	Article
Status:	Published
DOI:	10.3390/diseases13010024
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
School/Department:	London Campus
URI:	https://ray.yorksj.ac.uk/id/eprint/11442

University Staff: Request a correction | RaY Editors: Update this record